Using CRISPR-Cas9 technology for targeted nanopore sequencing

Gilpatrick T, Lee I, et al. (2019) Targeted nanopore sequencing with Cas9 for studies of methylation, structural variants and mutations. bioRxiv 604173, DOI 10.1101/604173

Citation summary: Read how custom guide RNA can be used in conjunction with high-fidelity Cas9 for targeted sequencing in nanopore sensing technology. Alt-R HiFi Cas9 V3 Nuclease, Alt-R CRISPR-Cas9 tracrRNA, and crRNA enable customizable, scalable sequencing with a fraction of the time and cost of previously-used sequencing protocols.


Current targeted sequencing strategies are often expensive, time-intensive, and either require a large amount of input sample, or offer low yield or limited read length. There is a need for fast, inexpensive, flexible, but comprehensive, sequencing options.

Nanopore sensing involves embedding a tiny hole, or nanopore, into an electrically resistant, polymer membrane, and using the nanopore to detect molecules that contact it. When a molecule passes through or blocks the nanopore, the current is disrupted. That disruption can be measured. DNA bases, RNA bases, modified bases, proteins, and small molecules can all be detected and identified in this way. A strand of DNA can be sequenced in real time as it passes through the nanopore, allowing for sequencing of much longer reads than was previously possible.

Nanopore Cas9-Targeted Sequencing, or “nCATS,” combines nanopore sequencing technology with Cas9–guide RNA technology for targeted sequencing (Figure 1). Cas9, or CRISPR associated protein 9, is an enzyme that cuts DNA. The Cas9–guide RNA complex, the ribonucleoprotein (RNP) complex, introduces cuts in genomic DNA at specific sites, allowing for sequencing of select regions to reveal DNA methylation, single nucleotide mutations, and structural variations. This method is both scalable and customizable. The whole process requires ~3 µg of genomic DNA and can be completed in a matter of hours, reducing time and cost, and increasing efficiency.


Gilpatrick, et al. tested nCATS using genomic DNA (gDNA) from 4 cell lines: the well-characterized GM12878 lymphoblast cell line and 3 breast cell lines (MCF-10A, MCF-7, and MDA-MB-231). Ten genomic regions, chosen based on existing expression data from these cell lines, were targeted. A custom panel of guide RNAs, selected for optimal on- and off-target performance, was designed using the custom Alt-R CRISPR-Cas9 crRNA design tool. RNP complexes were constructed by combining the guide RNA, composed of custom Alt-R CRISPR-Cas9 crRNA and tracrRNA, with Alt-R HiFi Cas9 Nuclease V3. This high-fidelity Cas9 provides highly efficient and specific genome editing with reduced off-target effects. After incubating the RNP complexes with gDNA for Cas9 cleavage, the sequencing adapters were ligated to the resulting fragments, and libraries were prepared. Sequencing was run using the GridION® sequencer (Oxford Nanopore Technologies) (Figure 1). Analyses were performed by both samtools [1] and nanopolish [2].

Schematic of nanopore Cas9-targeted sequencing library preparation

Figure 1. Schematic of Cas9 enrichment operation. ROI = region of interest. DNA ends are first dephosphorylated, new cuts introduced with Cas9/guideRNA complex, nanopore sequencing adaptors are ligated to cuts around the ROI and the sample is loaded to the nanopore sequencer.

Copyright: The copyright holder of Figure 1 is the author/funder of Gilpatrick, et al., 2019. It is made available under a CC-BY 4.0 International license.



Since the Cas9 RNP directs the sequencing adapter ligation, and the nanopores can sense native DNA strands, PCR amplification is not needed, allowing for more accurate sequencing. Ten- to 300-fold enrichment was achieved in all 10 evaluated regions, resulting in 20X to 800X coverage. Current sequencing technologies are limited by read length; the nanopore sensing allows for longer reads, but that might be at the cost of uniform quantification. Longer strands are associated with less uniform quantification. This is due to the variation in DNA fragment length influencing the concentration of free DNA ends, which impacts the efficiency of adapter ligation.

Nanopore methylation calls were compared to published whole genome bisulfite sequencing data and RNA sequencing data. The nanopore methylation patterns were very similar to the published data. Additionally, methylation signature noise around transcriptional start sites was reduced in the nanopore data compared to the published data. Noise indicates variation. The cleaner signature suggests that regulatory elements, like CPGs, may have less methylation variation, demonstrating an inverse correlation between gene activity and promoter methylation. CPG methylation may be playing a regulatory role.

Structural variation revealed by nCATS was compared to data from the Genome In A Bottle Consortium project from 10x Genomics. The variant caller, Sniffles [3], used on both 10x Genomics and nCATS data, initially failed to recognize reads, identifying them as homozygous. When Gilpatrick, et al., adjusted the sensitivity of Sniffles, structural variants were accurately called as heterozygous. Using the nCATS method, structural variant calling can be combined with methylation calling to study methylation at deletion points.

The results from single nucleotide variant detection were analyzed by both samtools and nanopolish and compared. samtools and nanopolish both evaluate variant calling, but nanopolish also takes into account electrical data from the nanopore. While some variants were called with higher confidence than others, overall, nanopolish had a much higher sensitivity and its use resulted in a lower false positive rate than samtools. nCATS, combined with nanopolish, can be used to identify both known and de novo variants.

The results presented here demonstrate the viability of nCATS as a reliable sequencing protocol that can be used to reveal methylation, structural variation, and single nucleotide variation. This targeted approach provides a faster, cost-effective method for evaluating clinically relevant genomic or epigenomic variation.

Published May 22, 2019

Your Advocate for the Genomics Age